Amarin Corporation (AMRN) PT Raised to $51 at H.C. Wainwright; REDUCE-IT Update is a 'Home run'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. SMCI
6. GOOGL
7. RTX
8. COF
9. TSLA
10. META

Go back to Amarin Corporation (AMRN) PT Raised to $51 at H.C. Wainwright; REDUCE-IT Update is a 'Home run'

Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Poin

November 11, 2018 10:32 AM EST

CHICAGO, Nov. 11, 2018 /PRNewswire/ -- Amarin Corporation plc (NASDAQ: AMRN), announced today the primary results from the Vascepa® (icosapent ethyl) cardiovascular (CV) outcomes trial, REDUCE-IT, following presentation of the late-breaking clinical trial results at the 2018 Scientific Sessions of the American Heart Association (AHA) in Chicago, Illinois.  REDUCE-IT primary results confirmed 25% relative risk reduction (RRR) for the topline primary endpoint result with multiple robust demonstrations of efficacy, including 20% reduction in cardiovascular death.

Experience the interactive Multichannel News Release here: ... More